Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients.
Heitmann JS, Jung S, Wacker M, Maringer Y, Nelde A, Bauer J, Denk M, Hoenisch-Gravel N, Richter M, Oezbek MT, Dubbelaar ML, Bilich T, Pumptow M, Martus P, Illerhaus G, Denzlinger C, Steinbach F, Aulitzky WE, Müller MR, Dörfel D, Rammensee HG, Salih HR, Walz JS.
Heitmann JS, et al. Among authors: martus p.
Front Immunol. 2024 Nov 26;15:1482715. doi: 10.3389/fimmu.2024.1482715. eCollection 2024.
Front Immunol. 2024.
PMID: 39660140
Free PMC article.
Clinical Trial.